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Joseph A. Dearani, MD,a Christopher G. McGregor, MD,a and Thomas A. Orszulak, MDaObjective: Improved durability of bioprostheses has led some surgeons to recommend
biologic rather than mechanical prostheses for patients younger than 65 years. We
compared late results of contemporary bioprostheses and bileaflet mechanical pros-
theses in patients who underwent aortic valve replacement between 50 and 70 years
old.
Methods: In this retrospective study, patients received either St Jude bileaflet valves or
Carpentier–Edwards bioprostheses. Operations were performed between January
1991 and December 2000, and groups were matched one-to-one according to age,
sex, need for coronary artery bypass grafting, and valve size.
Results: Four hundred forty patients were matched, and follow-up was 92% complete,
with median durations of 9.1 years for patients who received mechanical valves and
6.2 years for patients who received bioprostheses. The 5- and 10-year unadjusted
survivals were 87% and 68% for mechanical valves and 72% and 50% for bioprosthe-
ses, respectively (P , .01). Freedoms from reoperation at 10 years were 98% for
mechanical valves and 91% for bioprostheses (P5 .06). Rates of late stroke or other
embolic events and of endocarditis were similar between groups. Hemorrhagic com-
plications necessitating hospitalization occurred in 15% of patients with mechanical
valves and 7% of patients with bioprostheses (P 5 .01). Notably, 19% of patients
with bioprostheses were receiving warfarin sodium at last follow-up. After adjustment
for unmatched variables, including diabetes, renal failure, lung disease, New York
Heart Association functional class, ejection fraction, and stroke, the use of a mechan-
ical valve was protective against late mortality (hazard ratio 0.46, P , .01).
Conclusion: In this study, patients aged 50 to 70 years who underwent aortic valve
replacement with mechanical valves had a survival advantage relative to matched
patients who received bioprostheses. These findings question recommendations of
bioprostheses for younger patients and suggest that a randomized trial may be
warranted.
T
he current American Heart Association guidelines1 recommend mechanical
prostheses for aortic valve replacement (AVR) in patients younger than 65
years to avoid the risks of reoperation.Many surgeons believe that this age cut-
off should be lowered because of the improved durability of bioprosthetic valves,
which do not require anticoagulation with warfarin sodium.2-4 Evidence for this prac-
tice, however, is lacking. To the contrary, some believe that mechanical aortic valves
should be offered to all patients up to 70 years of age because of the greater longevity
of the general population and risks associated with reoperation.5
The selection of aortic valve prostheses for patients between 50 and 70 years old
thus remains controversial. In this study, we investigated late mortality and clinical
outcomes after insertion of a bioprosthetic or mechanical aortic valve in patients 50
to 70 years old.
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Materials and Methods
After institutional review board approval was obtained, we identi-
fied patients who underwent AVR with or without coronary artery
bypass grafting between January 1, 1991, and December 31,
2000. Inclusion criteria included patients who were aged 50 to 70
years at the time of surgery and had either a St Jude mechanical
bileaflet valve (St Jude Medical Inc, Minneapolis, Minn) or a
Carpentier-Edwards bioprosthetic valve (model numbers 2625,
2700, and 2800; Edwards Lifesciences LLC, Irvine, Calif) im-
planted in the aortic position. These two valve types were chosen be-
cause they were commonly implanted during this period and are still
implanted today. Exclusion criteria included mitral, tricuspid, or
pulmonary valve surgery and aortic or aortic root surgery.
Patients were matched one-to-one according to age (62 years),
sex, presence of coronary artery bypass grafting, and valve size. A
power calculation estimated that approximately 220 patients per
group were required to have a minimum of 80% power to detect
a 10% difference in mortality between the two groups with a 2-sided
a of .05. This power calculation assumed survival at 10 years after
AVR to be approximately 65%. Patient characteristics were pro-
spectively recorded in a clinical database at the time of surgery.
These variables included demographic characteristics, risk factors,
operative details, and early outcomes (within 30 days of surgery)
according to the definitions in the Society of Thoracic Surgeons
National Database.
Late outcomes (later than 30 days after surgery) were collected
from the electronic medical record and from questionnaires mailed
to patients by our survey research center. All positive answers
were checked against the medical record whenever possible. Re-
ports of additional cardiac operations were reviewed in detail.
Each patient’s vital status was checked through Accurint (Lexis-
Nexis, New York, NY) and the Social Security Death Index.
Statistics were performed with SAS statistical software (SAS In-
stitute, Inc, Cary, NC). Results for continuous data are reported as
mean 6 SD or median with interquartile range as appropriate and
for categoric data as the number and percentage of each category
from the observed total. To compare categoric variables between
valve groups c2 tests (or Fisher exact tests for sparse data) were
used, whereas t tests (or Wilcoxon rank sum tests for nonnormal
data) were used to compare continuous parameters among preoper-
ative, operative, early, and late complications. Kaplan–Meier actu-
arial survival methods were used to assess stroke, bleeding, late
survival, and reoperation as a function of time since surgery. The
groups were compared with a log-rank test. All estimates are
provided with 95% confidence intervals (CIs). Cox proportional
hazards regression was used to discriminate prognostic factors asso-
ciated with time to death. Candidate variables considered for multi-
variate analysis were those detected by univariate models as having
a significant association (P , .05) or suggestive trend toward asso-
ciation (P .05–.10) with mortality. To discriminate independent risk
factors, multivariate modeling was performed with methods of step-The Journal of Thorawise selection, with valve group and candidate variables all compet-
ing for entry into a final model predicting late mortality.
Results
A total of 439 patients with St Jude mechanical valves and
264 patients with Carpentier-Edwards bioprosthetic valves
were found. After matching as described previously, our final
study population consisted of a total of 220 patients in each
group (Figure 1). Follow-up was 92% complete, with mean
durations of 8.6 years (median 9.1 years, interquartile range
5.99–11.95 years) for patients who received mechanical
valves and 6.3 years (median 6.2 years, interquartile range
4.50–9.62 years) for patients who received bioprostheses.
Important patient variables, including clinical characteris-
tics, are presented in Table 1. The patient groups were similar
for all variables except age, which was 0.9 years higher in the
bioprosthesis group (66.6 vs 65.7 years, P , .01). In addi-
tion, the mean cardiopulmonary bypass and crossclamp dura-
tions were statistically significantly higher, although not
clinically significantly so, in the bioprosthetic group by 5.4
and 4.2 minutes, respectively (P 5 .03 for each; Table 1).
Early complications were assessed (Table 2). There was
a higher perioperative mortality in the bioprosthetic group
(5.5% vs 1.8%, P 5 .04). In the mechanical valve group,
the deaths were all caused by cardiac-related causes. In the
bioprosthesis group, there were 7 cardiac-related deaths, 1
cardiac tamponade, 1 aortic dissection, 1 pulmonary failure,
1 liver failure, and 1 hemorrhagic stroke. There were also
trends toward higher rates of reoperation for bleeding among
patients receiving bioprosthetic valves (P5 .08). There were
no differences between the groups in early incidences of tran-
sient ischemic attack, stroke, reoperation for valvular prob-
lems, and readmission to hospital.
At late follow-up, more patients reported a diagnosis of
atrial fibrillation in the mechanical valve group (35.6% vs
25.4%, P 5 .03; Table 3). The 10-year rate of freedom
1110 isolated AVR +/- CABG
1990 to 2000 in pt 50-70 y
332 removed - not CE
bioprosthesis or St. Jude bileaflet
mechanical
510 St. Jude +/- CABG 257 CE +/- CABG
220 matched 1:1 age, gender,
CABG, valve size
220 matched 1:1 age, gender,
CABG, valve size
Figure 1. Flow diagram detailing patient selection. AVR, Aortic
valve replacement; CE, Carpentier-Edwards valve; CABG, coronary
artery bypass grafting.cic and Cardiovascular Surgery c Volume 135, Number 4 879
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the bioprosthesis group (91.4%, CI 85.8%–95.8%) and the
mechanical valve group (93.2%, CI 88.9%–97.3%; P 5
.07). There were also no differences in incidences of late tran-
sient ischemic attack and embolus between the mechanical
TABLE 1. Preoperative and intraoperative patient
characteristics
Covariate MV (n 5 220) BPV (n 5 220) P value
Male (No.) 156 (70.9%) 154 (70.0%) .83
Age (y, mean 6 SD) 65.7 6 3.9 66.6 6 4.1 ,.01
Body mass index
(kg/m2, mean 6 SD)
28.7 6 4.7 28.5 6 5.5 .27
Body surface area
(m2, mean 6 SD)
2.0 6 0.2 2.0 6 0.3 .25
NYHA class III or IV (No.) 140 (63.9%) 160 (72.7%) .16
Smoking history (No.) 125 (56.8%) 141 (64.1%) .12
Diabetes (No.) 33 (15.0%) 38 (17.3%) .52
Renal failure (No.) 10 (4.6%) 11 (5.5%) .82
Endocarditis (No.) 10 (4.6%) 8 (3.6%) .63
Lung disease (No.) 33 (15.0%) 42 (19.1%) .25
Peripheral vascular
disease (No.)
34 (15.4%) 42 (19.1%) .31
Mean ejection fraction
(%, mean 6 SD)
54.1% 6 16.1% 56.4% 6 15.0% .20
Urgent or emergency
status (No.)
7 (3.2%) 11(5.0%) .46
Previous cardiac
surgery (No.)
31 (14.1%) 30 (13.6%) .89
Cardiopulmonary bypass
time (min, mean 6 SD)
96.5 6 51.7 101.9 6 43.3 .03
Crossclamp time
(min, mean 6 SD)
63.0 6 29.0 67.2 6 26.7 .03
Coronary artery bypass
grafting (No.)
110 (50.0%) 110 (50.0%) ..99
Median valve size (mm) 23 23 ..99
Patch root enlargement
(No.)
14 (6.4%) 14 (6.4%) ..99
MV, Mechanical valve; BPV, bioprosthetic valve; NYHA, New York Heart
Association.
TABLE 2. Early complications (within 30 days)
MV (n 5 220) BPV (n 5 220)
Covariate No. % No. % P value
Reoperation for bleeding 5 2.3% 12 5.5% .08
Early valve reoperation 1 0.5% 0 0.0% ..99
Mediastinitis 1 0.5% 3 1.4% .62
Early stroke 4 1.8% 3 1.4% ..99
Early transient ischemic attack 3 1.4% 2 0.9% ..99
Readmission to hospital 14 6.5% 15 6.9% .85
Perioperative death 4 1.8% 12 5.5% .04
MV, Mechanical valve; BPV, bioprosthetic valve.880 The Journal of Thoracic and Cardiovascular Surgery c Aprivalve and bioprosthesis groups (P5 .72 and P. .99, respec-
tively). Hemorrhagic complications necessitating hospitali-
zation occurred in 15% of patients with mechanical valves
and in only 7% of patients with bioprostheses (P5 .01). Be-
cause of the shorter follow-up interval in the bioprosthesis
group, however, we calculated the risks of bleeding at 10
years as 13.7% (CI 8.3%–19.2%) in the mechanical valve
group and 6.4% (CI 1%–12.3%) in the bioprosthesis group
(P 5 .06; Figure 2).
More patients in the mechanical valve group were receiv-
ing warfarin sodium at follow-up, although a substantial
number of patients in the bioprosthesis group also were re-
ceiving warfarin sodium (98% vs 19.3%). Of the 3 patients
in the mechanical valve group who were not receiving warfa-
rin sodium, 2 had undergone late reoperation with the im-
plantation of a bioprosthetic valve. In the third case, we
were unable to determine why the patient was not receiving
warfarin sodium. In the bioprosthetic group, of the 38 pa-
tients (19.3%) who were receiving warfarin sodium, 3 had
been taking the drug before surgery. Thus a total of 35 pa-
tients (17.8%) were newly treated with warfarin sodium.
Similar numbers of patients in both groups were receiving
aspirin, but more patients in the bioprosthesis group were
receiving clopidogrel bisulfate (7.1% vs 2%, P 5 .01).
Freedom from reoperation on the aortic valve was not sig-
nificantly different between the mechanical valve and bio-
prosthesis groups at 10 years (97.5% vs 91%, P 5 .13;
Figure 3). Freedom from all late reoperations was not signif-
icantly different at 10 years: mechanical valve 96.7% (CI
83.9%–97.3%) and bioprosthesis 90.4% (CI 83.9%–97.3%,
P 5 .29). The 5- and 10-year unadjusted survivals were,
TABLE 3. Outcomes at late follow-up (beyond 30 days)
MV (n 5 205) BPV (n 5 205)
Covariate No. % No. % P value
Late atrial fibrillation 73 35.6% 50 25.4% .03
Late stroke 19 9.3% 16 8.1% .68
Late transient ischemic
attack
13 6.4% 13 6.6% .92
Late endocarditis 6 2.9% 7 3.6% .72
Late bleeding requiring
hospitalization
31 15.1% 13 6.6% .01
Late embolus 4 2.0% 3 1.5% ..99
Warfarin sodium 202 99% 38 19.3% ,.01
Clopidogrel bisulfate 4 2.0% 14 7.1% .01
Aspirin 72 35.3% 113 35.3% ..99
Hospitalization for
cardiac cause
60 29.1% 53 26.9% ..99
Last NYHA class III or
IV
19 14.9% 17 17.3% .51
MV, Mechanical valve; BPV, bioprosthetic valve; NYHA, New York Heart
Association.l 2008
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for the mechanical valve group and 72% (CI 66%–78%)
and 50% (CI 52%–58%) for the bioprosthesis group (P ,
.01 for both; Figure 4). Causes of death are listed in Table
4. Survival of matched patients was compared with survival
of all patients aged 50 to 70 years who underwent AVR with
either a St Jude mechanical valve (n 5 510) or Carpentier-
Edwards bioprosthesis (n 5 257) between 1990 and 2000
to ensure that the matched patients were representative of
the entire cohort. Survivals were similar, indicating a repre-
sentative sample (Figure 5).
Increased age (P , .01), diabetes (P , .01), renal failure
(P, .01), chronic lung disease (P, .01), peripheral vascular
Figure 2. Freedoms from late bleeding events necessitating hospi-
talization and transfusion for patients who received either bio-
prosthetic or mechanical aortic valves.
Figure 3. Freedom from late reoperation on the aortic valve for pa-
tients who received either bioprosthetic or mechanical aortic
valves.The Journal of Thodisease (P 5 .01), increasing New York Heart Association
functional class (P , .01), concomitant coronary artery by-
pass grafting (P 5 .01), decreased ejection fraction (P ,
.01), and increased crossclamp and cardiopulmonary bypass
times (P5 .04 and P5 .01, respectively) were all predictors
of late mortality in univariate analyses. In the multivariate
analysis, increased age, diabetes, renal failure, lung disease,
advanced New York Heart Association functional class, in-
creased body mass index, and decreased ejection fraction
were all independent predictors of late mortality (Table 5).
In addition, a mechanical valve was protective for late sur-
vival (hazard ratio 0.48, CI 0.35–0.67, P , .01).
Discussion
We perceive a growing trend toward recommending biopros-
thetic valves to younger patients (,65 years). The rationale
for this strategy is based on improved durability of biopros-
thetic valves, anticipated low risk of reoperation, and avoid-
ance of long-term anticoagulation with warfarin sodium.
Data on long-term survival of patients with these prosthetic
valve types, however, are conflicting.
Figure 4. Overall survival of patients who received either me-
chanical or bioprosthetic aortic valves.
TABLE 4. Causes of death as listed on death certificate or
autopsy report
Cause of death MV (n 5 69) BPV (n 5 108)
Cardiac 27.5% 25.9%
Unknown 33.3% 32.4%
Cancer 10.1% 13.9%
Stroke, bleeding, or pulmonary
embolism
11.6% 10.2%
Pulmonary 8.7% 6.5%
Sepsis 1.4% 3.7%
Other 7.2% 7.4%
MV, Mechanical valve; BPV, bioprosthetic valve.racic and Cardiovascular Surgery c Volume 135, Number 4 881
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with mechanical valves relative to those with bioprosthetic
valves. In the Veterans Administration Cooperative Study
on Valvular Heart Disease, a prospective, randomized trial,
patients who underwent AVR with mechanical valves had
greater survival at 15 years than those who received biopros-
thetic valves (79% 6 3% vs 66% 6 3%, P 5 .02).6 In the
Edinburgh randomized trial, a survival advantage for
mechanical valves was present at 12 years, but at 20 years
the survival curves converged, and the small remaining dif-
ference was not statistically significant (25% vs 23%, P 5
.39).7 In a recent retrospective analysis, however, Hanania
and associates8 also demonstrated better survival for patients
who received mechanical prostheses (46% vs 32%, P5 .04).
Other retrospective studies that compared outcomes of pa-
tients with current-generation mechanical and bioprosthetic
valves have reported no important differences in late survival
between the two valve types.9-12 Chan and colleagues10 com-
pared outcomes of patients receiving three different biopros-
theses with those of a group of patients who had one of two
Figure 5. Survivals of entire cohort of patients undergoing aortic
valve replacement relative to matched patients demonstrate rep-
resentative sampling.
TABLE 5. Independent predictors of late mortality
Covariate Hazard ratio 95% CI P value
Mechanical valve 0.48 0.35–0.67 ,.01
Ejection fraction (per 1% elevation) 0.98 0.97–0.99 ,.01
Body mass index 1.04 1.01–1.07 .02
Age (per year) 1.08 1.03–1.14 ,.01
NYHA functional class 1.33 1.06–1.67 .01
Diabetes 1.79 1.23–2.59 .01
Chronic lung disease 1.98 1.29–2.69 ,.01
Renal failure 3.08 1.74–5.44 ,.01
CI, Confidence interval; NYHA, New York Heart Association.882 The Journal of Thoracic and Cardiovascular Surgery c Aprtypes of bileaflet mechanical valve.10 They found no differ-
ence in valve-related deaths in age categories similar to pa-
tients in our study. From what appears to be the same
cohort of patients, Prasongsukarn and coworkers12 reported
both valve-related and overall mortalities among patients in
patients aged 61 to 70 years undergoing AVR; interestingly,
in that study, no difference was evident for valve-related late
mortality, but there was an overall survival advantage for pa-
tients who received a mechanical prosthesis relative to those
who received a bioprosthetic aortic valve (4.06% mortality/
patient-year vs 5.5% mortality/patient-year, P 5 .016).
In our study, patients with bileaflet mechanical valves had
better survival than did case-matched patients with biopros-
theses (hazard ratio 0.46, CI 0.33–0.64). We chose to report
overall mortality, rather than cardiac-specific mortality or
valve-related mortality, because it was impossible to deter-
mine causes of death reliably for all patients. Indeed, without
autopsy reports, cause of death (and valve relatedness) is of-
ten subjective. In North America, autopsy rates are low, and
death certificates are notoriously unreliable for patients with
cardiac disease.13-15
Freedom from reoperation on the prosthetic aortic valve
was similar between groups, although there was a trend to-
ward more reoperations in the bioprosthesis group. Biopros-
thetic valves have a reported freedom from structural valve
deterioration ranging between 54% at 15 years to 96% at
12 years,16,17 suggesting that our follow-up may not have
been long enough to detect any difference in late reoperation.
In addition, our mean patient age was 66 years, which may
allow for greater durability of the bioprosthetic valves. In
2004, the life expectancy for Americans at age 65 was 18.7
years (17.1 years for men and 20 years for women).18 In light
of the durability of today’s bioprosthetic valves, it would ap-
pear that many patients who receive a bioprosthetic valve
who are younger than 70 years will require a reoperation as
an octogenarian, with a potentially increased mortality and
morbidity. Whereas aortic valve reoperation mortality as
low as 5% has been reported in patients with a mean age of
64 years,19 mortality may be as high as 17.4% in octogenar-
ians.20
An important argument in favor of bioprosthetic valves is
the freedom from chronic anticoagulation with warfarin so-
dium. It should be noted, however, that in our study a signif-
icant number of patients with bioprosthetic valves were
receiving warfarin sodium or clopidogrel bisulfate at late fol-
low-up. It is important to recognize that patients receive anti-
coagulation therapy for many reasons, and implantation of
a bioprosthetic valve does not ensure that a patient will avoid
anticoagulation. These patients are also at risk for atrial fibril-
lation, transient ischemic attacks, and stroke, which may
necessitate long-term anticoagulation. There were more pa-
tients in the bioprosthesis group who were receiving clopi-
dogrel bisulfate at last follow-up. This may be because
those in the mechanical valve group were already receivingil 2008
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tions related to peripheral vascular disease.
Freedom from major bleeding at 10 postoperative years
was better for patients in the bioprosthesis group than for
those in the mechanical valve group (93.8% vs 86.5%), al-
though the bleeding rate in the bioprosthesis group was not
negligible. It is possible that anticoagulant-related complica-
tions may decrease in the future with the introduction of
home international normalized ratio monitoring systems
that potentially would allow lower levels of anticoagulation
in patients with mechanical valves.21 There were no differ-
ences in the incidence of stroke between the two groups. Sim-
ilar to other studies,7,8 there was no difference in late
thromboembolism between patients with mechanical valves
and those with bioprosthetic valves.
There are several plausible explanations for the findings in
this study. Lower survival of patients with bioprostheses may
have been due to deaths related to unrecognized bioprosthetic
failure. Patients may not have been referred for reoperation or
may simply have refused a second or third aortic valve oper-
ation because of advanced age or comorbidities. Alterna-
tively, there may have been some hemodynamic benefit for
patients with mechanical aortic valves. It is also possible
that clinicians implanted mechanical valves preferentially
in individuals who generally appeared healthier and thus
more likely to outlive a bioprosthetic valve. It is true as
well, however, that many active, healthy patients who wished
to avoid anticoagulation may have requested and received
bioprostheses.
Our study is retrospective, and as such is subject to selec-
tion bias. We attempted to minimize patient differences by
the case-matching design and by subsequent multivariate
modeling techniques. The resulting patient groups were sim-
ilar with respect to most characteristics and comorbid condi-
tions. A number of surgeons operated during this period, and
some had stronger opinions regarding bioprosthetic or me-
chanical valves for this age group. In a retrospective study,
however, surgical bias can never be eliminated or adjusted
for retrospectively through propensity matching or other
statistical techniques.
Conclusions
Our study adds equipoise to the notion of valve choice in pa-
tients 50 to 70 years of age.We observed improved survival of
patients who received mechanical prostheses. There is
insufficient evidence to recommend bioprosthetic valves in
the aortic position for patients younger than 65 years, and pro-
spective randomized trials are needed to clarify the situation.
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Discussion
DrMatthew S. Slater (Portland, Ore). I thank the Association and
Brown and colleagues for this opportunity to discuss what I think is
an excellent study of an important topic. Briefly, this study repre-
sents another important contribution from the cardiac surgery pro-
gram at the Mayo Clinic. Brown and colleagues retrospectively
reviewed their experience with patients receiving aortic valves.
They first used matching to sort their patients and then subjected
the data to multivariate analysis. They found an association between
mechanical valve use and improved short- and long-term survivals.
Despite its limitations as a retrospective study, I think this article has
considerable value. I have several questions and comments.
First, I think this article could be titled, "Surgeons at the Mayo
Clinic Are Very Good at Selecting Their Patients." I think we all rec-
ognize that, despite the statistics and despite the guidelines and
whatever multivariate analysis kicks out, if you sit in an office
and you evaluate a patient and you can often tell how he or she is
going to do. As you suggested, Dr Brown, a prospective study
would help resolve this effect.
My first question is why the short-term survival was so different
despite matching. Specifically, why do you think the perioperative
mortalities are so disparate?
Dr Brown.We looked at the causes of death of those patients. In
the mechanical valve group, they were all cardiac causes of death. In
the bioprosthetic valve group, most also had a cardiac cause of death.
There were also a case each of aortic dissection, tamponade, hemor-
rhagic stroke, pulmonary-related death, and liver-related death.
Dr Slater. My second question is about why you choose to do
such a limited matching and then a multivariate analysis rather884 The Journal of Thoracic and Cardiovascular Surgery c Apthan a more complex matching strategy or a propensity score. Alter-
natively, you could perform a large multivariate analysis of the en-
tire cohort, because matching not only excludes those matched
variables from analysis but also excludes some patients. Why did
you choose this strategy?
Dr Brown. We were actually quite successful at our matching
and did not eliminate very many patients. There were about 30 pa-
tients in the bioprosthetic valve group who could not be matched
against the mechanical valve group. We chose to do this simply be-
cause it is an efficient way to look at this question. We could have
done a propensity matching analysis, but I am not sure whether it
would have given us any different answers.
Dr Slater. Did you have sufficient numbers to look at patients
aged 50 to 60 years and then 60 to 70 years, or was the number
too small? I know you did a power analysis.
Dr Brown. We did a power analysis for the overall group, and
we did have adequate power to detect late survival, which was our
primary outcome. In terms of the age groups of 50 to 60 years and
60 to 70 years, our patient numbers would have been smaller, al-
though we did look at age and it did not change any of our outcomes.
Dr Slater. Finally, if the valve choice is so central to patient out-
comes, why do you think the causes of death were so similar be-
tween the groups and did not seem to be altered by the valve
choice? They seem to be dying of many of the same things.
Dr Brown. You are correct, but I think that it goes to the under-
lying problem with determining cause of death for these patients.
Without an autopsy, many patients who have undergone cardiac
surgery will have a cardiac cause of death listed regardless of
whether that in fact was their cause of death. No one will ever
know. In addition, we also had difficulty, as everyone does, in ob-
taining death certificates for many patients, because now with
Health Insurance Portability and Accountability Act rules it is be-
coming increasingly difficult to access death certificates from
many states.ril 2008
